Estrategias lúdicas que aplica la docente en el Proceso de Enseñanza Aprendizaje de la comprensión lectora en los alumnos del tercer grado “A’’ del Colegio Público Gabriela Mistral, ubicado en Villa Miguel Gutiérrez del distrito VI de la ciudad de Managua, durante el I semestre del año escolar 2019

Este trabajo muestra en qué medida las estrategias lúdicas que aplica la docente en el proceso de enseñanza aprendizaje, se relacionan con los factores que inciden en la enseñanza de la comprensión lectora en los alumnos de tercer grado “A” y mediante la propuesta de actividades lúdicas se puede mejorar la comprensión lectora, por tanto dar una posible solución a estos agentes que inciden en el proceso de la lectura. La investigación realizada por medio de la prueba diagnóstica que se les aplicó a 16 alumnos de tercer grado “A” del Colegio Público Gabriela Mistral, se identificó según los resultados obtenidos: el nivel de comprensión lectora que poseen y que por ende han logrado alcanzar en los primeros meses del año escolar 2019. Por otro lado se realizaron entrevistas y guías de observación a la Docente en la asignatura de Lengua y Literatura, para indagar a fondo la problemática, según lo obtenido, se contrastó la información recopilada con la teoría y la práctica docente. Teniendo en cuenta el buen uso de las estrategias lúdicas en el proceso de la comprensión lectora, este trabajo, propone actividades pedagógicas que respondan a las necesidades educativas y a la vez crear un ambiente placentero y significativo para cada alumno al momento de llevar a cabo el proceso de lectura comprensiv

Memorias de la semana de la Facultad de Educación / VI Semana: Investigaciones educativas y pedagógicas.

El presente libro, publicado en la Editorial de la Corporación Universitaria Minuto de Dios – UNIMINUTO, reúne las memorias de la VI Semana de la Facultad de Educación – FEDU “Investigaciones Educativas y Pedagógicas”, evento que se realiza cada año con el fin de intercambiar experiencias académicas, culturales y deportivas entre los estudiantes y profesores de la Facultad, con la participación de otras Universidades interesadas en compartir sus experiencias en el campo de la investigación, la cultura y el deporte. La temática para la VI Semana de la FEDU en 2016 estuvo relacionada con la investigación en torno a la educación y la pedagogía, de tal forma que los profesores y los estudiantes tuvieron la oportunidad de intercambiar experiencias desarrolladas en los proyectos y en los semilleros de investigación; además, los estudiantes y los egresados tuvieron la oportunidad de presentar los resultados de sus trabajos de grado y otros estudios productos de investigación

I simposio Internacional sobre Investigación en la enseñanza de las ciencias

Edición 202

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

© 2023Background: The benefit of pharmacogenetic testing before starting drug therapy has been well documented for several single gene–drug combinations. However, the clinical utility of a pre-emptive genotyping strategy using a pharmacogenetic panel has not been rigorously assessed. Methods: We conducted an open-label, multicentre, controlled, cluster-randomised, crossover implementation study of a 12-gene pharmacogenetic panel in 18 hospitals, nine community health centres, and 28 community pharmacies in seven European countries (Austria, Greece, Italy, the Netherlands, Slovenia, Spain, and the UK). Patients aged 18 years or older receiving a first prescription for a drug clinically recommended in the guidelines of the Dutch Pharmacogenetics Working Group (ie, the index drug) as part of routine care were eligible for inclusion. Exclusion criteria included previous genetic testing for a gene relevant to the index drug, a planned duration of treatment of less than 7 consecutive days, and severe renal or liver insufficiency. All patients gave written informed consent before taking part in the study. Participants were genotyped for 50 germline variants in 12 genes, and those with an actionable variant (ie, a drug–gene interaction test result for which the Dutch Pharmacogenetics Working Group [DPWG] recommended a change to standard-of-care drug treatment) were treated according to DPWG recommendations. Patients in the control group received standard treatment. To prepare clinicians for pre-emptive pharmacogenetic testing, local teams were educated during a site-initiation visit and online educational material was made available. The primary outcome was the occurrence of clinically relevant adverse drug reactions within the 12-week follow-up period. Analyses were irrespective of patient adherence to the DPWG guidelines. The primary analysis was done using a gatekeeping analysis, in which outcomes in people with an actionable drug–gene interaction in the study group versus the control group were compared, and only if the difference was statistically significant was an analysis done that included all of the patients in the study. Outcomes were compared between the study and control groups, both for patients with an actionable drug–gene interaction test result (ie, a result for which the DPWG recommended a change to standard-of-care drug treatment) and for all patients who received at least one dose of index drug. The safety analysis included all participants who received at least one dose of a study drug. This study is registered with ClinicalTrials.gov, NCT03093818 and is closed to new participants. Findings: Between March 7, 2017, and June 30, 2020, 41 696 patients were assessed for eligibility and 6944 (51·4 % female, 48·6% male; 97·7% self-reported European, Mediterranean, or Middle Eastern ethnicity) were enrolled and assigned to receive genotype-guided drug treatment (n=3342) or standard care (n=3602). 99 patients (52 [1·6%] of the study group and 47 [1·3%] of the control group) withdrew consent after group assignment. 652 participants (367 [11·0%] in the study group and 285 [7·9%] in the control group) were lost to follow-up. In patients with an actionable test result for the index drug (n=1558), a clinically relevant adverse drug reaction occurred in 152 (21·0%) of 725 patients in the study group and 231 (27·7%) of 833 patients in the control group (odds ratio [OR] 0·70 [95% CI 0·54–0·91]; p=0·0075), whereas for all patients, the incidence was 628 (21·5%) of 2923 patients in the study group and 934 (28·6%) of 3270 patients in the control group (OR 0·70 [95% CI 0·61–0·79]; p <0·0001). Interpretation: Genotype-guided treatment using a 12-gene pharmacogenetic panel significantly reduced the incidence of clinically relevant adverse drug reactions and was feasible across diverse European health-care system organisations and settings. Large-scale implementation could help to make drug therapy increasingly safe. Funding: European Union Horizon 2020